Biosynthesis of magnesium hydroxide nanomaterials using Monodora myristica, antioxidative activities and effect on disrupted glucose metabolism in streptozotocin-induced diabetic rat

The inhibitory mechanism of amylase inhibitors and research progress in nanoparticle-based inhibitors

Type 2 diabetes is caused by persistently high blood sugar levels, which leads to metabolic dysregulation and an increase in the risk of chronic diseases such as diabetes and obesity. High levels of rapidly digestible starches within foods may contribute to high blood sugar levels. Amylase inhibitors can reduce amylase activity, thereby inhibiting starch hydrolysis, and reducing blood sugar levels. Currently, amylase inhibitors are usually chemically synthesized substances, which can have undesirable side effects on the human body. The development of amylase inhibitors from food-grade ingredients that can be incorporated into the human diet is therefore of great interest. Several classes of phytochemicals, including polyphenols and flavonoids, have been shown to inhibit amylase, including certain types of food-grade nanoparticles. In this review, we summarize the main functions and characteristics of amylases within the human body, as well as their interactions with amylase inhibitors. A strong focus is given to the utilization of nanoparticles as amylase inhibitors. The information covered in this article may be useful for the design of functional foods that can better control blood glucose levels, which may help reduce the risk of diabetes and other diet-related diseases.

Ethnomedicinal Knowledge of Plants Used in Nonconventional Medicine in the Management of Diabetes Mellitus in Kinshasa (Democratic Republic of the Congo)

Background

People with diabetes, herbalists, and traditional medicine practitioners (TMPs) from Kinshasa use plants to treat diabetes, but no study has inventoried the plants used by these populations. The present study was conducted to identify the plants used in Kinshasa to treat diabetes mellitus.

Methods

The survey conducted in the form of a semistructured interview between March 2005 and August 2006 made it possible to collect ethnobotanical information from people with diabetes (n = 126), herbalists (n = 80), and TMPs (n = 120).

Results

The 326 subjects consulted (sex ratio M/F = 0.6, age 51 ± 7 years, and experience: 17 ± 5 years) provided information on 71 plants, most of which are trees (35%), belonging to 38 families dominated by Fabaceae (19.7%) and indicated in 51 other cases of consultation dominated by malaria (12%). From these 71 plants derived, 86 antidiabetic recipes were administered orally, where the leaf is the most used part (>50%) and the decoction (>46%) is the most common mode of preparation. This study reports for the first time the antidiabetic use of 11 species, among which Tephrosia vogeliiX (0.08), Chromolaena corymbosaX (0.06), and Baphia capparidifoliaX (0.06) present the highest consensus indexes (CI) and Marsdenia latifoliaW (UVp = 0.08) and Rauvolfia manniiX (UVp = 0.06) present the highest UVs.

Conclusion

The results show that Kinshasa people treat diabetes using several plants. Some are specific to the ecological environment; others are used in other regions. Pharmacological studies are underway to assess the therapeutic efficacy of these plants.

Antioxidant evaluation and computational prediction of prospective drug-like compounds from polyphenolic-rich extract of Hibiscus cannabinus L. seed as antidiabetic and neuroprotective targets: assessment through in vitro and in silico studies

BACKGROUND

Reports have implicated diabetes mellitus (DM) and Alzheimer's disease (AD) as some of the global persistent health challenges with no lasting solutions, despite of significant inputs of modern-day pharmaceutical firms. This study therefore, aimed to appraise the in vitro antioxidant potential, enzymes inhibitory activities, and as well carry out in silico study on bioactive compounds from polyphenolic-rich extract of Hibiscus cannabinus seed (PEHc).

METHODS

In vitro antioxidant assays were performed on PEHc using standard methods while the identification of phytoconstituents was carried out with high performance liquid chromatography (HPLC). For the in silico molecular docking using Schrodinger's Grid-based ligand docking with energetics software, seven target proteins were retrieved from the database ( https://www.rcsb.org/ ).

RESULTS

HPLC technique identified twelve chemical compounds in PEHc, while antioxidant quantification revealed higher total phenolic contents (243.5 ± 0.71 mg GAE/g) than total flavonoid contents (54.06 ± 0.09 mg QE/g) with a significant (p < 0.05) inhibition of ABTS (IC₅₀ = 218.30 ± 0.87 µg/ml) and 1, 1-diphenyl-2-picrylhydrazyl free radicals (IC₅₀ = 227.79 ± 0.74 µg/ml). In a similar manner, the extract demonstrated a significant (p < 0.05) inhibitory activity against α-amylase (IC₅₀ = 256.88 ± 6.15 µg/ml) and α-glucosidase (IC₅₀ = 183.19 ± 0.23 µg/ml) as well as acetylcholinesterase (IC₅₀ = 262.95 ± 1.47 µg/ml) and butyrylcholinesterase (IC₅₀ = 189.97 ± 0.82 µg/ml), respectively. Furthermore, In silico study showed that hibiscetin (a lead) revealed a very strong binding affinity energies for DPP-4, (PDB ID: 1RWQ) and α-amylase (PDB ID: 1SMD), gamma-tocopherol ( for peptide-1 receptor; PDB ID: 3C59, AChE; PDB ID: 4EY7 and BChE; PDB ID: 7B04), cianidanol for α-glucosidase; PDB ID: 7KBJ and kaempferol for Poly [ADP-ribose] polymerase 1 (PARP-1); PDB ID: 6BHV, respectively. More so, ADMET scores revealed drug-like potentials of the lead compounds identified in PEHc.

CONCLUSION

As a result, the findings of this study point to potential drug-able compounds in PEHc that could be useful for the management of DM and AD.